Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

ibrutinib 3Vincristine 2Methotrexate 2tozasertib 1thymoglobulin 1romiplostim 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1lucatumumab 1fludarabine 1fenebrutinib 1enzastaurin 1duvelisib 1Receptors, Chimeric Antigen 1Prednisone 1Prednisolone 1Hydrocortisone 1Hu-Mik-beta-1 monoclonal antibody 1Doxorubicin 1Dasatinib 1Cytarabine 1Cyclophosphamide 1Busulfan 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphoid × lucatumumab × Clear all
NCT00108108 2012-10-01

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Novartis

Phase 1 Terminated
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡